GET DAILY SIGNALSGilead Sciences (GILD): Path to the $190 Target and 14% Upside Potential
Key Takeaways
- The central target of $190 is the average of the verified analyst price targets that sit above the current share price, not a published consensus figure.
- At a recent close near $166.89, reaching $190 would require roughly a 14% advance — a substantial but not extreme move.
- Across 14 individual targets reviewed, the full range runs from $131 to $200, and the overall mean of all targets is about $177.
- Bullish targets rest on the strength of Gilead's HIV franchise — including Biktarvy and the newer Yeztugo PrEP launch — plus oncology optionality.
- Cautious targets reflect oncology pipeline setbacks, margin pressure, and early generic competition for Yeztugo.
- You can explore Major News, Today's Price Move, Forecast, and Earnings for GILD on additional pages.
- For automated stock monitoring, explore Trending AI Robots.
Understanding Analyst Price Targets for GILD
Gilead Sciences, Inc. (GILD) is a Foster City, California-based biopharmaceutical company best known for its HIV medicines, its Kite cell-therapy oncology business, and its liver-disease portfolio. Wall Street coverage skews bullish, with most tracked firms rating the stock Buy or Overweight.
Because the overall mean of all valid targets sits only about 6% above the latest price, the $190 figure used here is calculated as the average of the targets that exceed the current share price. Across 14 individually attributed targets reviewed, the range spans from $131 (RBC Capital) to $200 (Scotiabank and Needham), with an overall average of roughly $177. The 10 targets above the current price — from firms including J.P. Morgan ($190), UBS ($195), Citi ($188), Wells Fargo ($190), Morgan Stanley ($183), Truist ($181), TD Cowen ($175) and BMO Capital ($184) — average about $188.6, rounded to $190. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The gap between bullish and cautious views is wide. Optimists emphasize durable HIV cash flows and the Biktarvy patent extension, while firms such as Goldman Sachs ($155), Cantor Fitzgerald ($155) and Leerink Partners ($145) reflect a more restrained view of oncology progress and competitive pressures. These targets are individual forecasts, not guarantees.
GILD's Current Market Position and the Path to the Target
GILD closed near $166.89 on November 6, 2026, not far below a 52-week high around $176.58. A move to $190 implies about 14% upside — a substantial move for a large-cap stock already up roughly 38% year-to-date. The path would likely depend on sustained HIV growth, continued oncology data readouts, and whether recent enthusiasm around ASH 2026 blood-cancer results and positive Livdelzi liver-disease data converts into durable multiple expansion.
Factors That Could Support a Move Higher
The core bull case centers on the HIV franchise. Biktarvy remains a key revenue driver, and the twice-yearly Yeztugo (lenacapavir) PrEP launch offers a new growth runway. Analysts at UBS and J.P. Morgan raised targets after Gilead's third-quarter beat, citing HIV momentum. Oncology optionality — including Kite's cell therapies and the anito-cel program — plus the Biktarvy patent extension and recent positive liver-disease data provide additional support. Third-quarter revenue grew about 6.8% year over year to $8.3 billion.
Risks That Could Keep the Target Out of Reach
Earnings quality is a concern: third-quarter EPS fell roughly 20% year over year to $1.94 on rising costs, and the second quarter included a large GAAP net loss tied to impairment charges. The FDA's approval of a first generic Yeztugo raises competitive risk to a key growth asset, and Gilead's oncology pipeline has produced mixed results. A valuation compression, a pullback in biotech sentiment, or policy and pricing uncertainty could all keep the stock below the $190 mark.
Technical Levels and Market Structure
GILD trades above its 50-day and 200-day moving averages, a constructive long-term setup, but it recently reversed sharply after touching a 52-week high in premarket trading — a sign of profit-taking near resistance. The area around $176–$178 now marks key resistance, while the $153–$155 zone offers nearby support. The psychological $200 level, which matches the highest analyst targets, would represent the next major milestone beyond $190. From what I see, reviewing patterns with Tickeron’s AI Real Time Patterns helped confirm the resistance levels.
Time Horizon and What Investors Should Monitor
Most analyst price targets reflect a research horizon of roughly 12 months, though individual firms may differ. Key items to watch include quarterly HIV and oncology sales, Yeztugo launch trends and generic competition, guidance updates, further pipeline and clinical data, and any regulatory or pricing-policy developments. Analyst revisions around earnings will be the most direct signal on whether the $190 target remains in view. I’m watching this closely as earnings approach.
Final Assessment
Can GILD reach $190? The question is not a forecast but a test of conviction in the HIV franchise and oncology pipeline. The $190 central target, derived from the average of above-price analyst targets, requires about a 14% advance from current levels. Durable HIV cash flows and new PrEP momentum support the case, while margin pressure, oncology uncertainty, and early Yeztugo generics are the principal obstacles. The wide $131-to-$200 analyst range shows genuine disagreement, making earnings, guidance, and data readouts the clearest indicators to monitor next.
Using Tickeron’s AI Daily Buy/Sell Signals in My Process
In my own research workflow, Tickeron’s AI Daily Buy/Sell Signals provide a helpful layer of continuous monitoring across thousands of stocks. The AI-driven signals help spot shifts in technical behavior and market conditions that complement fundamental analysis on names like GILD. I find this approach efficient for tracking evolving opportunities without replacing my own due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GILD's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for GILD turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 38 of 54 cases over the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on GILD as a result. In 55 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
Following a +7.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 216 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 167 of 278 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
Bearish Trend Analysis
The 10-day RSI Indicator for GILD moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 22 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 63 cases where GILD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.495) is normal, around the industry mean (-1.421). GILD's P/E Ratio (-63.943) is considerably lower than the industry average of (21.700). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.038) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor